In a clinical trial involving 945 patients with stage III or IV melanoma, the survival rates of patients treated with Ipilimumab (a CTLA-4 inhibitor) and Nivolumab (a PD-1 inhibitor) in combination were investigated and compared to those receiving monotherapy with either drug. The gene discussed is PDCD1; the disease is melanoma.